TCM
CYTK icon

Teza Capital Management’s Cytokinetics CYTK Stock Holding History

Teza Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,488
Closed -$446K – 435
2024
Q4 		$446K Buy
+9,488
New +$493K 0.07% 302
2024
Q2 		– Sell
-7,952
Closed -$558K – 616
2024
Q1 		$558K Buy
7,952
+5,190
+188% +$401K 0.07% 323
2023
Q4 		$231K Buy
+2,762
New +$100K 0.04% 469
2020
Q3 		– Sell
-10,372
Closed -$244K – 428
2020
Q2 		$244K Buy
+10,372
New +$194K 0.05% 445
2020
Q1 		– Sell
-39,881
Closed -$423K – 214
2019
Q4 		$423K Buy
+39,881
New +$410K 0.12% 322

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Teza Capital Management's CYTK Position: Q1 2025 in Review

Teza Capital Management sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 9,488 shares — an estimated $446K sold.

Teza Capital Management first reported a position in CYTK in Q4 2019 and held it in 5 quarters. The position peaked at $558K in Q1 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Teza Capital Management reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Teza Capital Management sold 9,488 Cytokinetics shares in Q1 2025, an estimated $446K.
  • Teza Capital Management first reported a position in Cytokinetics in Q4 2019 and held it in 5 quarters.
  • Teza Capital Management's Cytokinetics position peaked at $558K in Q1 2024.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Teza Capital Management's 13F filing for Q1 2025, filed 15 May 2025.